BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 7242306)

  • 1. [Pharmacodynamics, pharmacokinetics and metabolism of isosorbide nitrates in the awake dog].
    Dietmann K; Sponer G; Voss E
    Med Welt; 1981 Apr; 32(14A):481-91. PubMed ID: 7242306
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
    Kogi K; Tanaka O; Kimura T; Saito T
    Nihon Yakurigaku Zasshi; 1982 Oct; 80(4):279-88. PubMed ID: 7152395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hemodynamic effect, effect duration and pharmacokinetics of 80 mg of isosorbide-5-mononitrate in acute myocardial infarct].
    Reifart N; Bussmann WD; Schirmer M; Kaltenbach M
    Med Welt; 1981 Apr; 32(14A):540-2. PubMed ID: 7242317
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs.
    Sponer G; Kühnle HF; Strein K; Bartsch W; Endele R; Dietmann K
    J Pharmacol Exp Ther; 1984 Jan; 228(1):235-9. PubMed ID: 6694105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nitrite and methemoglobin formation in dogs following oral isosorbide dinitrate, isosorbide-2-mononitrate and isosorbide-5-mononitrate].
    Strein K; Dietmann K; Bartsch W
    Med Welt; 1981 Apr; 32(14A):499-502. PubMed ID: 7242308
    [No Abstract]   [Full Text] [Related]  

  • 6. Simultaneous determination of isosorbide dinitrate and its mononitrates in human plasma by capillary column GLC.
    Rosseel MT; Bogaert MG
    J Pharm Sci; 1979 May; 68(5):659-60. PubMed ID: 430513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative clinical evaluation of ISDN and 5-ISMN as exemplified by Mono Mack 20 mg/40 mg].
    Schmidt G
    Med Welt; 1983 Jun; 34(25-26):732-3. PubMed ID: 6888243
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhalation of carbon dioxide enhances the coronary vasodilating action of isosorbide dinitrate in the dog.
    Nakamura J; Zhang SW; Ishikawa N
    Jpn J Pharmacol; 1987 Feb; 43(2):221-5. PubMed ID: 3106686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tolerance or hemodynamic adaptation during nitrate therapy].
    Rietbrock N; Woodcock BG
    Dtsch Med Wochenschr; 1984 Feb; 109(5):163-5. PubMed ID: 6697904
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacokinetics, effect and tolerance of isosorbide dinitrate and isosorbide-5-mononitrate in healthy persons].
    Abshagen U; Spörl-Radun S; Betzien G; Kaufmann B; Endele R
    Med Welt; 1981 Apr; 32(14A):508-16. PubMed ID: 7242310
    [No Abstract]   [Full Text] [Related]  

  • 11. Systemic and coronary vascular effects of the 2- and the 5-mononitrate esters of isosorbide.
    Wendt RL
    J Pharmacol Exp Ther; 1972 Mar; 180(3):732-42. PubMed ID: 4622308
    [No Abstract]   [Full Text] [Related]  

  • 12. Simultaneous measurement of plasma isosorbide dinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate by gas-liquid chromatography.
    Richard L; Klein G; Orr JM
    Clin Chem; 1976 Dec; 22(12):2060-1. PubMed ID: 1000812
    [No Abstract]   [Full Text] [Related]  

  • 13. [Effects of isosorbide dinitrate on systemic haemodynamics, regional coronary blood flow and ST-segment. A study on normal and/or ischaemic dog heart (author's transl)].
    Berdeaux A; Giudicelli JF
    Nouv Presse Med; 1982 Jun; 11(27):2043-7. PubMed ID: 7110963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between pharmacokinetics and pharmacodynamics of organic nitrates.
    Jähnchen E
    Z Kardiol; 1986; 75 Suppl 3():12-5. PubMed ID: 3099483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitrate tolerance: hemodynamic effects of intravenous isosorbide dinitrate after sustained oral isosorbide dinitrate administration.
    Kumagae H; Koiwaya Y; Tanaka K
    Clin Ther; 1990; 12(1):31-43. PubMed ID: 2328526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative hemodynamic study of IS-5-MN and ISDN in man--which are equieffective doses?
    Vogt A; Bernhardt S; Schwarck H; Stroh E; Kreuzer H
    Z Kardiol; 1983; 72 Suppl 3():182-4. PubMed ID: 6666220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ITF 296, a new endothelium-independent vasodilator: comparison with nitroglycerin and isosorbide dinitrate.
    Ghaleh B; Dubois-Randé JL; Hittinger L; Berdeaux A; Giudicelli JF
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S6-12. PubMed ID: 8839220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics and pharmacodynamics of a new 80 mg oral delayed-action isosorbide dinitrate preparation].
    Pello JY; Auclert L; Rey E; Joly H; Mialet C; Puechavy C; Georges M; Ruffo M; Olive G
    Arch Mal Coeur Vaiss; 1992 Apr; 85 Spec No 1():13-6. PubMed ID: 1530422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Experimental research on a delayed-release pharmaceutical preparation of isosorbide dinitrate].
    Imperatore A; Turtur A; Sannino A; Sconamiglio R; Chieppa S
    Boll Chim Farm; 1979 Nov; 118(11):667-79. PubMed ID: 553529
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of oral molsidomine effects on ventricular function and dimensions in the conscious dog.
    Fiedler VB; Göbel H; Nitz RE
    Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):56-75. PubMed ID: 6409016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.